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INTRODUCTION
Colorectal cancer (CRC) is one of the most 
common malignancy with high morbidity and mortality 
worldwide, accounting for almost 1.4 million new cases 
and 0.7 million deaths in 2012 [1]. In China, the estimated 
new cases of CRC were 376,300, with 191,000 deaths 
occurring in 2015 [2]. Despite of improvements in 
diagnosis and treatment for CRC, its annual new incidence 
and mortality is still growing. 
CRC is a heterogeneous disease with complex 
multi-pathways. Most of CRC follows the chromosomal 
instability (CIN) pathway which is the most well 
characterized pathway type [3]. The Wnt signaling 
pathway [4], RAS pathway [5], p53 system [6], and other 
pathways involved in CIN [7, 8] are frequently present 
to be dysregulated during the initiation, progression 
and metastasis of CRC. A number of patients have 
quite different treatment responses and prognoses 
although their tumor types are histologically identical. 
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ABSTRACT
Colorectal cancer (CRC) is a major cause of global cancer mortality. Gene 
expression profiles can help predict prognosis of patients with CRC. In most of previous 
studies, disease recurrence was analyzed as the survival endpoint. Thus we aim to build 
a robust gene signature for prediction of overall survival (OS) in patients with CRC. 
Fresh frozen CRC tissues from 64 patients were analyzed using Affymetrix HG-U133plus 
2.0 gene arrays. By performing univariate survival analysis, 6487 genes were found 
to be associated with the OS in our cohort. KEGG analysis revealed that these genes 
were mainly involved in pathways such as endocytosis, axon guidance, spliceosome, 
Wnt signalling and ubiquitin mediated proteolysis. A seven-gene signature was further 
selected by a robust likelihood-based survival modelling approach. The prognostic 
model of seven-gene signature (NHLRC3, ZDHHC21, PRR14L, CCBL1, PTPRB, PNPO, 
and PPIP5K2) was constructed and weighted by regression coefficient, which divided 
patients into high- and low-risk groups. The OS for patients in high-risk group was 
significantly poorer compared with patients in low-risk group. Moreover, all seven 
genes were found to be differentially expressed in CRC tissues as compared with 
adjacent normal tissues, indicating their potential role in CRC initiation and progression. 
This seven-gene signature was further validated as an independent prognostic marker 
for OS prediction in patients with CRC in other two independent cohorts. In short, we 
developed a robust seven-gene signature that can predict the OS for CRC patients, 
providing new insights into identification of CRC patients with high risk of mortality. 
                                                     Research Paper
Oncotarget95055www.impactjournals.com/oncotarget
Therefore it is necessary to look deeply into those 
abnormal molecular pathways and develop individual 
strategies for CRC diagnosis and therapy. To date, 
a lot of efforts have been put to identify molecular 
markers, however, with limited success achieved when 
focusing on single protein or gene mutation [9]. Gene 
expression profiling has been verified as a promising 
tool to classify tumors and predict the prognosis of 
cancer [10]. Identification of molecular subtypes 
[11, 12], discovery of progression markers [13, 14], 
and construction of different prognostic models [15–18] 
in CRC have been processed and confirmed to potentially 
improve the diagnosis and therapy of CRC. However, all 
the developed prognostic signatures are still difficult to 
apply commonly because of the heterogeneity of CRC. 
For most of these studies, disease free survival 
(DFS) or relapse free survival (RFS) was used as the 
endpoint to develop molecular markers or to evaluate the 
validity of prognosis. Considering that overall survival 
(OS) is traditionally regarded as the ultimate measure of 
treatment benefits, we would like to investigate whether it 
is possible to build a robust gene signature to predict the 
OS in CRC patients. By performing univariate survival 
analysis, 6487 genes associated with OS were discovered 
in patients with CRC from a Chinese cohort. Of them, 
a seven-gene signature was developed using a robust 
likelihood-based survival modelling approach, and further 
trained by BRB-array tool to generate a prognostic model. 
Importantly, the prognostic value of this seven-gene 
signature was validated in other two independent cohorts, 
indicating its potential use for identifying CRC patients 
with high risk of mortality.
RESULTS 
The overall flowchart of this work was summarized 
in Figure 1. We employed Cox proportional hazard 
regression model and forward selection method to identify 
a seven-gene signature which can predict OS for colorectal 
cancer patients based on our gene microarray datasets of 
Chinese patients. To further evaluate the performance of 
this gene signature, two cohorts on different platforms 
from other countries were subsequently validated.
Identification of genes associated with OS
Our data included expression values of 54675 genes 
and 64 samples. Each sample had observed (survival or 
censoring) time and censoring status. We first selected 
an initial set of genes by performing univariate survival 
analysis using Cox proportional hazard regression model, 
with the threshold of p-value set as 0.05. Total 6487 
genes associated with the overall survival were initially 
identified. 
To investigate the key pathways that were associated 
with patient survival, we next performed KEGG pathway 
enrichment analysis for the 6487 genes. These genes were 
found to be enriched in the signalling pathways such as 
endocytosis, axon guidance, spliceosome, Wnt signalling 
and ubiquitin mediated proteolysis (Figure 2A).
Screening of seven-gene signature
We next screened the optimal survival-associated 
signature genes based on a partial likelihood of the Cox 
proportional hazard regression model [21]. Considering 
larger variability of the data, a cross-validation technique 
was applied by separating the samples into training 
and validation sets (See Materials and Methods). A 
forward selection was employed to generate a series of 
gene models and the optimal model was then selected 
by using the criterion of minimal AIC (Table 1). Seven 
genes (NHLRC3, ZDHHC21, PRR14L, CCBL1, PTPRB, 
PNPO and PPIP5K2) were selected as signature genes that 
can optimally predict the OS of patients with CRC. With 
the selected gene signature, unsupervised hierarchical 
clustering analysis was performed, and the patient 
population was classified into two sub-classes: Cluster 1 
and Cluster 2 (Figure 2B). Compared with Cluster 1 
patients, all Cluster 2 patients in this study were still alive 
during follow-up (Figure 2C). Therefore this seven-gene 
signature may have important application in predicting the 
OS for patients with CRC.
Differential expressions of seven-gene signature 
in colorectal cancer and adjacent normal tissue
We further compared the expressions of these 
seven genes between CRC tissues and adjacent normal 
tissues in two independent data sets. In our cohort, the 
mRNA expression of CCBL1, NHLRC3 and PNPO were 
significantly down-regulated in 26 CRC as compared with 
paired adjacent normal tissues (Figure 2D). On the other 
hand, PRR14L, PPIP5K2, PTPRB and ZDHHC21 were 
determined to be over-expressed in CRC (Figure 2D). 
Consistent result was obtained using TCGA cohort that 
contained 623 CRC and 51 adjacent normal tissues 
(Figure 2E). Therefore, these seven genes may play 
important roles as oncogenes or tumor suppressor genes 
during the development of CRC. 
Construction of survival risk score system based 
on seven-gene signature
We subjected these seven genes to BRB-arrayTools 
to construct a survival risk score system by using the 
64 training samples. The regression coefficient for 
each gene was generated. The survival risk score was 
calculated as follows: risk score = (–1.004× expression 
level of PPIP5K2) + (0.823× expression level of CCBL1) 
+ (–0.715× expression level of PNPO) + (–0.008× 
expression level of PTPRB) + (–1.077× expression level 
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of PRR14L) + (–0.133× expression level of NHLRC3) + 
(–0.781× expression level of ZDHHC21). Higher score 
indicated greater mortality risk for patient with CRC. By 
performing cross-validated time-dependent ROC curves, 
the area under the respective ROC Curves (AUC) was 
0.814 (Figure 3A), confirming the prediction accuracy of 
this model. 64 patients were divided into high- and low-
risk groups. The OS for patients in high-risk group was 
significantly poorer compared with patients in low-risk 
group (hazard ratio (HR) = 25.79, P < 0.001) (Figure 3B).
External validation of seven-gene signature
To evaluate the robustness and effectiveness of the 
seven-gene signature, we used two independent sets of 
CRC patients with OS information and gene expressions 
on different platforms. The first one was from the 
Vanderbilt Medical Center (GSE17537, N = 55) using 
the same gene expression array platform as we did. The 
second one, TCGA dataset (N = 584), used Illumina 
RNA Sequencing method. The survival risk score of 
Figure 1: Flow chart of methods for building the seven-gene signature based on 64 Chinese colorectal cancer (CRC) 
samples. Briefly, 6487 genes associated with the overall survival (OS) in CRC patients were first produced by univariate survival analysis. 
Next a robust likelihood-based survival modelling approach was used to select the optimal gene signature for prognosis prediction. The 
survival risk score system was built based on seven-gene signature (NHLRC3, ZDHHC21, PRR14L, CCBL1, PTPRB, PNPO, and 
PPIP5K2), which divided patients into high- and low-risk groups. Finally, this seven-gene signature was validated in two independent 
cohorts on different platforms.
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Table 1: Survival-associated gene signature screening using forward selection
Gene ID nloglik AIC Gene Symbol 
236953_s_at 63.51 129.01* NHLRC3 
243835_at 55.24 114.47* ZDHHC21 
236941_at 53.96 113.92* PRR14L 
206037_at 50.62 109.24* CCBL1 
230250_at 49.53 109.06* PTPRB 
222653_at 46.85 105.70* PNPO 
203253_s_at 43.87 101.73* PPIP5K2 
203031_s_at 43.86 103.73 
1557118_a_at 42.42 102.84 
242793_at 42.32 104.65 
205462_s_at 41.73 105.45 
1552319_a_at 40.57 105.15 
Figure 2: Identification of optimal gene signature for OS prediction. (A) Enrichment of Kyoto Encyclopedia of Genes and 
Genomes (KEGG) pathways analysis for 6487 genes associated with the OS. Top 10 pathways were shown. (B) The 6487 genes in 
64 samples were shown in a heat map (The green and the red colors represent lower and higher expression value, respectively). Unsupervised 
hierarchical clustering analysis was applied, which divided patients into two clusters. (C) Kaplan–Meier curves for patients in different 
clusters. (D) The mRNA expression of CCBL1, NHLRC3, PNPO, PRR14L, PPIP5K2, PTPRB and ZDHHC21 in 26 pairs of CRC tissues 
and adjacent normal tissues in our cohort. Data is represented by mean ± SD and p values were obtained by Wilcoxon matched-pairs test. 
(*p < 0.05, **p < 0.01, ***p < 0.001). (E) The mRNA expression of CCBL1, NHLRC3, PNPO, PRR14L, PPIP5K2, PTPRB and ZDHHC21 
in 623 CRC tissues and 51 adjacent normal tissues in TCGA cohort. Data is represented by mean ± SD and p values were obtained by 
Mann–Whitney U test. (*p < 0.05, **p < 0.01, ***p < 0.001).
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each patient was calculated based on expressions of 
seven-gene signature. ROC curve analyses demonstrated 
that this seven-gene signature was capable of predicting 
OS in patients with CRC (for cohort I, AUC = 0.715, 
p =  0.011; for cohort II, AUC = 0.585, p = 0.009) 
(Figure 4A and 4C). We further divided the patients into two 
risk groups, based on optimal cut-off risk scores (Figure 4A 
and 4C). For the first validation data set, 38 (69.1%) and 
17 (30.9%) patients were distinguished as the low and high 
risk groups, respectively. For the second validation data 
set, 418 (71.6%) and 166 (28.4%) patients were classified 
as low and high risk groups, respectively. Kaplan-Meier 
plots indicated significant differences between 5-year OS 
of two groups in both two validation data sets: GSE17537 
(p < 0.001, Figure 4B), and TCGA (p = 0.002, Figure 4D). 
By univariate (Table 2) and multivariate analyses (Table 3), 
this seven-gene signature significantly predicted the 5-year 
OS of patients. In multivariate analyses, this seven-gene 
signature showed prognostic significance for 5-year OS 
risk in both two validation data sets: GSE17537 (p = 0.002) 
and TCGA (p = 0.005). Therefore, the seven-gene signature 
was an independent prognostic factor in predicting the OS 
of patients with CRC.
To evaluate this seven-gene signature with respect 
to the prognosis among patients in TNM stage II and III, 
we further investigated the association between risk scores 
and OS in 382 CRC patients from TCGA. Stage III tumors 
were associated with a higher rate of 5-year mortality than 
stage II tumors (HR = 2.160, p = 0.004) (Figure 5A). 
Meanwhile, patients in high risk group demonstrated 
poorer survival as compared with patients in low risk 
group (HR = 2.918, p < 0.001) (Figure 5B). Moreover, this 
increased 5-year mortality in high risk group was marked 
in both stage II (HR = 3.124, p = 0.005) (Figure 5C) and 
stage III (HR = 2.415, p = 0.012) (Figure 5D). Therefore, 
this seven-gene signature might be able to help predict 
prognosis for patients with stage II and stage III CRC. 
DISCUSSION 
In this study, we presented the development and 
validation of a robust seven-gene signature which was 
able to predict the OS for CRC patients. The signature 
identified patients with high risk of mortality who may 
need potential interventions and individual therapies.
A Chinese cohort containing 64 CRC patients 
was used and total 6487 genes were identified to be 
associated with the overall survival. Of them, several 
genes have been reported to present prognostic value 
for CRC patients, such as CDX2 [19], EPHA2 [20], 
SLC2A1 [21], CDKN2A [22] and ITGA3 [23]. By 
performing KEGG analysis, these genes were enriched 
in the signalling pathways such as endocytosis, axon 
guidance, spliceosome, Wnt signalling and ubiquitin 
mediated proteolysis (Figure 2A). The activation of 
the Wnt signalling pathway is a critical event which 
frequently occur during CRC development, making it as 
therapeutic targets for cancer therapy [24]. The ubiquitin-
proteasome system is important for cell growth and 
apoptosis regulation, making it also a potential molecular 
target for cancer treatment and prevention [25]. We further 
narrowed down the genes size and selected an optimal 
seven-gene signature (NHLRC3, ZDHHC21, PRR14L, 
CCBL1, PTPRB, PNPO and PPIP5K2) for prognosis 
prediction. By searching NCBI (http://www.ncbi.nlm.
nih.gov/gene/), none of these seven genes have been 
reported previously in cancer study. Of note, NHLRC3 
was predicted to play role in protein modification process 
Figure 3: Construction of survival risk score system based on seven-gene signature. (A, B) A prognostic model was developed 
in BRB-ArrayTools software using penalized Cox regression of the seven-gene signature. Leave-one-out cross-validation (LOOCV) was 
employed to evaluate the accuracy of predicting OS in 64 CRC patients. (A) The cross-validated time-dependent ROC curve was generated for 
survival predictions with an AUC of 0.814. (B) Patients were divided into high- and low-risk groups by cross-validated Kaplan–Meier curve.
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Figure 4: Performance of seven-gene signature in predicting OS in CRC patients from two independent cohorts. (A, B) 
ROC and Kaplan–Meier curves for the seven-gene signature in dataset from Vanderbilt Medical Center (GSE17537, N = 55). (A) The ROC 
curve was generated for 3-year overall survival predictions with an AUC of 0.715 (p = 0.011). Optimal cut-off value (–7.788) was obtained 
to divide the patients into low and high risk groups. (B) Patients in high risk group had poorer OS as compared with patients in low risk 
group (HR = 4.475, p < 0.001). (C, D) ROC and Kaplan–Meier curves for the seven-gene signature in the TCGA dataset (N = 584). (C) The 
ROC curve was generated for 5-year overall survival predictions with an AUC of 0.585 (p = 0.009). Optimal cut-off value (–13.73) was 
obtained. (D) Patients in high risk group had poorer OS as compared with patients in low risk group (HR = 1.915, p = 0.002).
Table 2: Univariate Cox regression analysis of potential prognostic factors for patients with 
CRC
Cohort I  Cohort II 
Characteristics No. of Patients 5 yr SR (%) p value Characteristics No. of Patients 5 yr SR (%) p value 
Age 0.311 Age 0.042 
< = 60 25 72.0% < = 60 190 90.0% 
> 60 30 56.7% > 60 394 81.0% 
Gender 0.395 Gender 0.534
Female 29 58.6% Female 267 84.6% 
Male 26 69.2% Male 317 83.3% 
Pathologic_stage 0.100 Pathologic_stage < 0.001 
I, II 19 78.9% I 103 96.1% 
II 210 89.5% 
III, IV 36 55.6% III 172 82.0% 
IV 85 62.4% 
Risk 0.001 Risk 0.002 
Low 38 76.3% Low 418 86.8%
High 17 35.3% High 166 76.5%
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through ubiquitination; CCBL1, PNPO, PPIP5K2 and 
ZDHHC21 were possibly involved in cellular metabolism 
regulation or acting as cell signaling molecules; PTPRB 
is a member of the protein tyrosine phosphatase (PTP) 
family which is known to regulate a variety of cellular 
processes including oncogenic transformation [26]; the 
function of PRR14L remains unknown. Interestingly, we 
found that these genes were differentially expressed in 
CRC tissues compared with adjacent normal tissues in two 
different cohorts (Figure 2D and 2E). This suggests that 
these genes might be novel oncogenes or tumor suppressor 
genes, and that their functions need further investigation.
The prognostic signature was validated in two 
independent patient sets on different platforms from 
different countries, with further validation study from 
China currently underway. Indeed, By ROC curve 
analyses, this seven-gene signature was capable of 
predicting OS in patients with CRC from these two 
datasets with an AUC of 0.715 and 0.585, respectively 
(Figure 4A and 4C). By multivariate analyses, this seven-
gene signature was validated as an independent prognostic 
factor for predicting 5-year OS of CRC patients (Table 3). 
Comparing with other studies that constructed different 
prognostic models [15–18], our study obtained a signature 
with few genes (only seven) to successfully predict the 
OS in CRC patients. This is important to develop a RT-
PCR assay for clinical practice. In our future study, the 
high-risk patients identified by seven-gene signature will 
be further studied for their responses to different therapies 
in an independent Chinese cohort.
The American Joint Committee on Cancer (AJCC) 
TNM staging system is a golden standard to determine the 
treatment and prognosis for patients with CRC. However, 
the limitation of TNM staging system to accurately 
predict prognosis has been also demonstrated in clinical 
practice. For example, the 5-year survival rate of stage 
IIIA patients (85.4%) was higher than stage II patients 
(79.2%) [27]. Increasing attention has been focused on 
patients with stage II and stage III CRC, as the use of 
adjuvant chemotherapy to a proportion of these patients 
Figure 5: Association between seven-gene signature and OS in patients with stage II and III CRC. (A) For 382 CRC 
patients from TCGA, Stage III tumors were associated with greater 5-year mortality than stage II tumors. (B) 382 CRC patients were 
divided into high and low risk group based on their survival risk scores. The association between seven-gene signature (risk scores) and 
5-year OS in patients with stage II and III CRC was assessed simultaneously (panel B) or individually (stage II in panel (C); stage III in 
panel (D) by Kaplan–Meier curves.
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may cause potential under treatment or overtreatment 
[28–30]. To date, there are several tests (such as Oncotype 
Dx [31], a 12-gene RT-PCR assay, and Coloprint, an 
18-gene microarray [32]) being developed in clinical 
laboratories, which are intending to predict the prognosis 
of patients with stage II CRC and help guide the use of 
chemotherapy. Still, all of them are under evaluation in 
multiple validation cohorts. Our seven-gene signature 
is able to predict the OS for patients in stage II and III 
in TCGA cohort (Figure 5). However, the sample size is 
limited. Hence large samples are required to be collected 
in future to further validate the prognostic value of this 
seven-gene signature on CRC patients in stage II and III. 
Moreover, we will study whether the seven-gene signature 
could benefit selection of adjuvant chemotherapy for 
individual patient in stage II and III.
In conclusion, our seven-gene signature provides 
new promising biomarkers for CRC prognosis and 
potential therapeutic targets for CRC treatment. 
MATERIALS AND METHODS 
Human CRC Samples
Frozen tumor specimens (n = 64) and paired adjacent 
non-tumor tissue (n = 26) of 64 patients with colorectal 
cancer were retrieved from the Second Affiliated Hospital of 
Zhejiang University, College of Medicine, China. All patients 
who received surgical operation and were diagnosed as colon 
or rectal adenocarcinoma were included in this study. All 
pathologic information and follow-up data were obtained by 
reviewing the hospital records [33]. Notably, 19 of the 64 
patients died of cancer during follow-up. The clinical data of 
patients was presented in Table 4. This study was approved 
by the ethics committee of Zhejiang University.
Gene expression microarray and data analysis
Fresh CRC samples were immediately snap frozen 
in liquid nitrogen and stored at –80°C until further use. 
Total RNA was extracted using Trizol reagent (Invitrogen, 
Carlsbad, California, USA) and sent out to company 
(Capitalbio Corporation, Beijing, China) for RNA quality 
control (QC) performance. Only high quality RNA 
(OD260/280 = 1.8~2.2; 28S:18S ≥ 1.5; RIN (RNA Integrity 
Number) ≥ 8) were used for Affymetrix HG- U133plus 2.0 
gene array. Statistical analyses of microarray data were 
performed in the R language environment (http://www.r-
project.org) [34]. The data was normalized and transformed 
to expression values by using justRMA( ) function in “affy” 
library. Signal values for all genes were transformed to the 
log base 2. Quantile normalization was applied to obtain 
equal distributions of the probe signal intensities. 
Gene signature identification
A robust likelihood-based survival modeling 
approach [35] was used to select the gene signature. We 
implemented our analysis by using the “rbsurv” package 
in R. The detailed algorithm is summarized as follows:
Table 3: Multivariate Cox regression analysis of potential prognostic factors for patients with CRC
Cohort I  Cohort II 
Characteristics Exp(B) 95.0% CI for 
Exp(B)
p value Characteristics Exp(B) 95.0% CI for 
Exp (B)
p value 
Lower Upper Lower Upper 
Age Age 
< = 60 1.000 (ref) < = 60 1.000 (ref) 
> 60 1.836 0.718 4.694 0.204 > 60 2.384 1.367 4.158 0.002
Gender Gender 
Female 1.000 (ref) Female 1.000 (ref) 
Male 0.908 0.361 2.286 0.838 Male 0.991 0.648 1.517 0968
Pathologic_stage Pathologic_stage 
I, II 1.000 (ref) I 1.000 (ref) 
II 1.950 0.670 5.677 0.221
III, IV 2.382 0.748 7.591 0.142 III 4.418 1.554 12.562 0.005
IV 11.795 4.166 33.396 < 0.001
Risk Risk 
Low 1.000 (ref) Low 1.000 (ref) 
High 4.062 1.646 10.027 0.002 High 1.833 1.196 2.810 0.005
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(i). We randomly divided the samples into the 
training set with N*(1 − p) samples and the validation 
set with N*p samples, with p = 1/3. We fitted a gene to 
the training set of samples and obtained the parameter 
estimate for this gene. Then we evaluated log likelihood 
with the parameter estimate and the validation set of 
samples. This evaluation was repeated for each gene. 
(ii). We repeated the above procedure 10 times, thus 
obtaining 10 log likelihoods for each gene. The best gene, 
g(1), with the largest mean log likelihood was selected. 
(iii). We searched the next best gene by evaluating 
every two-gene model and selected an optimal one with 
the largest mean log likelihood. 
(iv). We continued this forward gene selection 
procedure, resulting in a series of models. Akaike 
information criterions (AICs) for all the candidate models 
were computed and an optimal model with the smallest 
AIC was selected finally. 
Unsupervised hierarchical clustering and 
Kaplan-Meier analysis
Unsupervised hierarchical clustering analysis 
[36] was performed in R using “hclust” function with 
Euclidean distance. Kaplan-Meier curves for two distinct 
groups of patients were plotted using “survfit” function in 
survival package. P value from log rank test was computed 
using “survdiff” function.
Development and validation of 7-gene survival 
risk score system
We subjected the seven genes to BRB-array Tools 
(http://linus.nci.nih.gov/BRB-ArrayTools.html), using 
survival risk group prediction tool [37], to calculate the 
regression coefficient for each gene using the 64 training 
samples from Zhejiang University. The Survival Risk 
Score is the sum of the product of the expression level of 
a gene and its corresponding regression coefficient. The 
patients were divided into two groups at high and low risk 
using the 50th percentile. Leave-one-out cross-validation 
method was performed to determine the robustness. 
Gene expression data from the Vanderbilt Medical 
Center (GSE17537, HG-U133_Plus_2 platform; N = 55) 
with overall survival information was normalized by 
justRMA( ) and used as the first validation data set [14]. 
The CRC dataset (N = 623 for primary CRC tumors and 
N = 51 for adjacent non-tumor tissues) from The Cancer 
Genome Atlas (TCGA, http://cancergenome.nih.gov/; 
Illumina GA or Hiseq platform) was analyzed (publicly 
Table 4: Patient characteristics
Variables
Case number (N = 67)
N (%) or mean (range)
Gender
 Male 41 (61.2%)
 Female 26 (38.8%)
Age (years)
 Male 61 (36–92)
 Female 54.5 (19–83)
TNM stage (T)
 T1 1 (1.5%)
 T2 6 (9.0%)
 T3 35 (52.2%)
 T4 25 (37.3%)
TNM stage (N)
 N0 25 (37.3%)
 N1 25 (37.3%)
 N2 17 (25.4%)
TNM stage (M)
 M0 49 (73.1%)
 M1 18 (26.9%)
TNM stage
 I 4 (6.0%)
 II 17 (25.4%)
 III 28 (41.8%)
 IV 18 (26.9%)
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available TCGA pre-processed data was downloaded 
from Broad GDAC Firehose (https://gdac.broadinstitute.
org/)), and those with overall survival information 
(N = 584) were used as the second validation set. For 
each independent cohort, the risk score of patients was 
calculated using the coefficient derived from the training 
data set. Receiver operating characteristic (ROC) curve 
analyses were generated for the 3- and 5-year survival 
predictions to evaluate the specificity and sensitivity of the 
gene signature and to estimate discriminatory power of the 
prognostic gene expression signatures. The area under the 
curve (AUC) was calculated and a bootstrap method was 
used to calculate the 95% confident internal (CI) for AUC. 
Optimal cut- off value based on ROC curve was obtained 
to divide the patients into low and high risk groups [38]. 
Kaplan-Meier curves for the two groups of patients were 
plotted using “survfit” function in survival package.
Enrichment analysis of kyoto encyclopedia of 
genes and genomes pathways
Genes that were associated with the overall survival 
of patients evaluated by Cox proportional hazard regression 
model (P < 0.05) were included in the Kyoto Encyclopedia 
of Genes and Genomes (KEGG) pathway enrichment 
analysis using the Gene Set Analysis Toolkit V2 (http://
bioinfo.vanderbilt.edu/webgestalt/). The hypergeometric 
test statistical method and the BH multiple test adjustment 
method were used. All genes from human beings were 
used as reference. Top 10 pathways with at least 10 genes 
involved were considered significantly enriched.
Statistical analysis
Mann–Whitney U test and Wilcoxon matched-
pairs test were performed to compare the gene expression 
between CRC and adjacent normal tissues. All statistical 
tests were performed using Graphpad Prism 5.0 (GraphPad 
Software Inc, San Diego, CA, USA), and a 2-tailed P value 
of less than 0.05 was considered statistically significant
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